{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T15:01:30Z","timestamp":1782226890143,"version":"3.54.5"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2021,10,27]],"date-time":"2021-10-27T00:00:00Z","timestamp":1635292800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,10,27]],"date-time":"2021-10-27T00:00:00Z","timestamp":1635292800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Coronavirus disease 2019 (COVID-19) antiviral response in a pan-tumor immune monitoring (CAPTURE) (\n                    <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03226886\">NCT03226886<\/jats:ext-link>\n                    ) is a prospective cohort study of COVID-19 immunity in patients with cancer. Here we evaluated 585 patients following administration of two doses of BNT162b2 or AZD1222 vaccines, administered 12 weeks apart. Seroconversion rates after two doses were 85% and 59% in patients with solid and hematological malignancies, respectively. A lower proportion of patients had detectable titers of neutralizing antibodies (NAbT) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VOC) versus wild-type (WT) SARS-CoV-2. Patients with hematological malignancies were more likely to have undetectable NAbT and had lower median NAbT than those with solid cancers against both SARS-CoV-2 WT and VOC. By comparison with individuals without cancer, patients with hematological, but not solid, malignancies had reduced neutralizing antibody (NAb) responses. Seroconversion showed poor concordance with NAbT against VOC. Previous SARS-CoV-2 infection boosted the NAb response including against VOC, and anti-CD20 treatment was associated with undetectable NAbT. Vaccine-induced T cell responses were detected in 80% of patients and were comparable between vaccines or cancer types. Our results have implications for the management of patients with cancer during the ongoing COVID-19 pandemic.\n                  <\/jats:p>","DOI":"10.1038\/s43018-021-00274-w","type":"journal-article","created":{"date-parts":[[2021,10,27]],"date-time":"2021-10-27T12:03:25Z","timestamp":1635336205000},"page":"1305-1320","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":132,"title":["Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the CAPTURE study"],"prefix":"10.1038","volume":"2","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7267-0981","authenticated-orcid":false,"given":"Annika","family":"Fendler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6208-173X","authenticated-orcid":false,"given":"Scott T. C.","family":"Shepherd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5877-8657","authenticated-orcid":false,"given":"Lewis","family":"Au","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9796-2040","authenticated-orcid":false,"given":"Katalin A.","family":"Wilkinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2074-6171","authenticated-orcid":false,"given":"Mary","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"Byrne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6900-6086","authenticated-orcid":false,"given":"Maddalena","family":"Cerrone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas M.","family":"Schmitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nalinie","family":"Joharatnam-Hogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Shum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zayd","family":"Tippu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karolina","family":"Rzeniewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4287-799X","authenticated-orcid":false,"given":"Laura Amanda","family":"Boos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Harvey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleanor","family":"Carlyle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Edmonds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lyra","family":"Del Rosario","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Sarker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karla","family":"Lingard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Mangwende","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy","family":"Holt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamid","family":"Ahmod","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justine","family":"Korteweg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tara","family":"Foley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Bazin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8166-2641","authenticated-orcid":false,"given":"William","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taja","family":"Barber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Emslie-Henry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyi","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille L.","family":"Gerard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daqi","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2732-4497","authenticated-orcid":false,"given":"Emma C.","family":"Wall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Agua-Doce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sina","family":"Namjou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Caidan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mike","family":"Gavrielides","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1464-8583","authenticated-orcid":false,"given":"James I.","family":"MacRae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7219-560X","authenticated-orcid":false,"given":"Gavin","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kema","family":"Peat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aida","family":"Murra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayleigh","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Molly","family":"O\u2019Flaherty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Dowdie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Ash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Firza","family":"Gronthoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7596-4555","authenticated-orcid":false,"given":"Robyn L.","family":"Shea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gail","family":"Gardner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darren","family":"Murray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"Kinnaird","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5077-6814","authenticated-orcid":false,"given":"Wanyuan","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3874-2782","authenticated-orcid":false,"given":"Javier","family":"Pascual","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Rodney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1097-7953","authenticated-orcid":false,"given":"Justin","family":"Mencel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1509-7023","authenticated-orcid":false,"given":"Olivia","family":"Curtis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clemency","family":"Stephenson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhavna","family":"Oza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheima","family":"Farag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isla","family":"Leslie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aljosja","family":"Rogiers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil","family":"Iyengar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Ethell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Messiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5158-1069","authenticated-orcid":false,"given":"David","family":"Cunningham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0286-8703","authenticated-orcid":false,"given":"Ian","family":"Chau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naureen","family":"Starling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Turner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liam","family":"Welsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"van As","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin L.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne","family":"Droney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana","family":"Banerjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate C.","family":"Tatham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"O\u2019Brien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Harrington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shreerang","family":"Bhide","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Okines","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Reid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J. S.","family":"Furness","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7579-340X","authenticated-orcid":false,"given":"Lisa","family":"Pickering","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4299-3018","authenticated-orcid":false,"given":"Charles","family":"Swanton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"The Crick COVID-19 Consortium","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Gandhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5331-639X","authenticated-orcid":false,"given":"Steve","family":"Gamblin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3052-0368","authenticated-orcid":false,"given":"David L. V.","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8457-2633","authenticated-orcid":false,"given":"George","family":"Kassiotis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4692-4554","authenticated-orcid":false,"given":"Sacheen","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2090-0025","authenticated-orcid":false,"given":"Nadia","family":"Yousaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1116-628X","authenticated-orcid":false,"given":"Shaman","family":"Jhanji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Nicholson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Howell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanna","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Wilkinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Larkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8846-136X","authenticated-orcid":false,"given":"Samra","family":"Turajlic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"The CAPTURE Consortium","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,27]]},"reference":[{"key":"274_CR1","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1038\/s41579-021-00573-0","volume":"19","author":"WT Harvey","year":"2021","unstructured":"Harvey, W. T. et al. SARS-CoV-2 variants, spike mutations and immune escape. Nat. Rev. Microbiol. 19, 409\u2013424 (2021).","journal-title":"Nat. Rev. Microbiol."},{"key":"274_CR2","unstructured":"Public Health England. Confirmed Cases of COVID-19 Variants Identified in UK https:\/\/www.gov.uk\/government\/news\/confirmed-cases-of-covid-19-variants-identified-in-uk (2021)."},{"key":"274_CR3","unstructured":"Public Health England and Department of Health and Social Care. COVID-19: Guidance on Protecting People Defined on Medical Grounds as Extremely Vulnerable https:\/\/www.gov.uk\/government\/publications\/guidance-on-shielding-and-protecting-extremely-vulnerable-persons-from-covid-19\/19-july-guidance-on-protecting-people-who-are-clinically-extremely-vulnerable-from-covid-19 (2021)."},{"key":"274_CR4","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1016\/S0140-6736(21)01358-1","volume":"397","author":"A Sheikh","year":"2021","unstructured":"Sheikh, A., McMenamin, J., Taylor, B. & Robertson, C. SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness. Lancet 397, 2461\u20132462 (2021).","journal-title":"Lancet"},{"key":"274_CR5","doi-asserted-by":"publisher","unstructured":"Brosh-Nissimov, T. et al. BNT162b2 vaccine breakthrough: clinical characteristics of 152 fully-vaccinated hospitalized COVID-19 patients in Israel. Clin. Microbiol. Infect. https:\/\/doi.org\/10.1016\/j.cmi.2021.06.036 (2021).","DOI":"10.1016\/j.cmi.2021.06.036"},{"key":"274_CR6","doi-asserted-by":"publisher","first-page":"n1088","DOI":"10.1136\/bmj.n1088","volume":"373","author":"J Lopez Bernal","year":"2021","unstructured":"Lopez Bernal, J. et al. Effectiveness of the Pfizer\u2013BioNTech and Oxford\u2013AstraZeneca vaccines on COVID-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case\u2013control study. BMJ 373, n1088 (2021).","journal-title":"BMJ"},{"key":"274_CR7","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71, 209\u2013249 (2021).","journal-title":"CA Cancer J. Clin."},{"key":"274_CR8","doi-asserted-by":"crossref","unstructured":"Kuderer, N. M. et al. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet 395, 1907\u20131918 (2020).","DOI":"10.1016\/S0140-6736(20)31187-9"},{"key":"274_CR9","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1016\/j.annonc.2021.02.024","volume":"32","author":"P Grivas","year":"2021","unstructured":"Grivas, P. et al. Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium. Ann. Oncol. 32, 787\u2013800 (2021).","journal-title":"Ann. Oncol."},{"key":"274_CR10","unstructured":"Lee, L. Y. W. et al. COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study. Lancet Oncol. 21, 1309\u20131316 (2020)."},{"key":"274_CR11","unstructured":"Garassino, M. C. et al. COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study. Lancet Oncol. 21, 914\u2013922 (2020)."},{"key":"274_CR12","doi-asserted-by":"crossref","unstructured":"Ribas, A. et al. Priority COVID-19 vaccination for patients with cancer while vaccine supply is limited. Cancer Discov. 11, 233\u2013236 (2020).","DOI":"10.1158\/2159-8290.CD-20-1817"},{"key":"274_CR13","unstructured":"Department of Health and Social Care. Joint Committee on Vaccination and Immunisation: advice on priority groups for COVID-19 vaccination, 30 December 2020 https:\/\/www.gov.uk\/government\/publications\/priority-groups-for-coronavirus-covid-19-vaccination-advice-from-the-jcvi-30-december-2020\/joint-committee-on-vaccination-and-immunisation-advice-on-priority-groups-for-covid-19-vaccination-30-december-2020 (2021)."},{"key":"274_CR14","doi-asserted-by":"crossref","unstructured":"Thakkar, A. et al. Seroconversion rates following COVID-19 vaccination among patients with cancer. Cancer Cell 39, 1081\u20131090 (2021).","DOI":"10.1016\/j.ccell.2021.06.002"},{"key":"274_CR15","doi-asserted-by":"crossref","unstructured":"Monin, L. et al. Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study. Lancet Oncol. 22, 765\u2013778 (2021).","DOI":"10.1016\/S1470-2045(21)00213-8"},{"key":"274_CR16","doi-asserted-by":"crossref","unstructured":"Massarweh, A. et al. Evaluation of seropositivity following BNT162b2 messenger RNA vaccination for SARS-CoV-2 in patients undergoing treatment for cancer. JAMA Oncol. 7, 1\u20138 (2021).","DOI":"10.1001\/jamaoncol.2021.2155"},{"key":"274_CR17","doi-asserted-by":"crossref","unstructured":"Addeo, A. et al. Immunogenicity of SARS-CoV-2 messenger RNA vaccines in patients with cancer. Cancer Cell 39, 1091\u20131098 (2021).","DOI":"10.1016\/j.ccell.2021.06.009"},{"key":"274_CR18","doi-asserted-by":"crossref","unstructured":"Herishanu, Y. et al. Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia. Blood 137, 3165\u20133173 (2021).","DOI":"10.1182\/blood.2021011568"},{"key":"274_CR19","doi-asserted-by":"publisher","first-page":"e542","DOI":"10.1016\/S2352-3026(21)00199-X","volume":"8","author":"SH Lim","year":"2021","unstructured":"Lim, S. H. et al. Antibody responses after SARS-CoV-2 vaccination in patients with lymphoma. Lancet Haematol. 8, e542\u2013e544 (2021).","journal-title":"Lancet Haematol."},{"key":"274_CR20","doi-asserted-by":"crossref","unstructured":"Roeker, L. E. et al. COVID-19 vaccine efficacy in patients with chronic lymphocytic leukemia. Leukemia 35, 2703\u20132705 (2021).","DOI":"10.1038\/s41375-021-01270-w"},{"key":"274_CR21","doi-asserted-by":"publisher","first-page":"e583","DOI":"10.1016\/S2352-3026(21)00169-1","volume":"8","author":"K Maneikis","year":"2021","unstructured":"Maneikis, K. et al. Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study. Lancet Haematol. 8, e583\u2013e592 (2021).","journal-title":"Lancet Haematol."},{"key":"274_CR22","doi-asserted-by":"crossref","unstructured":"Ghione, P. et al. Impaired humoral responses to COVID-19 vaccination in patients with lymphoma receiving B-cell directed therapies. Blood 138, 811\u2013814 (2021).","DOI":"10.1182\/blood.2021012443"},{"key":"274_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00528-x","volume":"11","author":"H Parry","year":"2021","unstructured":"Parry, H. et al. Antibody responses after first and second COVID-19 vaccination in patients with chronic lymphocytic leukaemia. Blood Cancer J. 11, 136 (2021).","journal-title":"Blood Cancer J."},{"key":"274_CR24","doi-asserted-by":"crossref","unstructured":"Ehmsen, S. et al. Antibody and T cell immune responses following mRNA COVID-19 vaccination in patients with cancer. Cancer Cell 39, 1034\u20131036 (2021).","DOI":"10.1016\/j.ccell.2021.07.016"},{"key":"274_CR25","doi-asserted-by":"crossref","unstructured":"Grifoni, A. et al. Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. Cell 181, 1489\u20131501 (2020).","DOI":"10.1016\/j.cell.2020.05.015"},{"key":"274_CR26","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.cell.2020.09.005","volume":"183","author":"L Au","year":"2020","unstructured":"Au, L. et al. Cancer, COVID-19, and antiviral immunity: the CAPTURE study. Cell 183, 4\u201310 (2020).","journal-title":"Cell"},{"key":"274_CR27","unstructured":"Bange, E. M. et al. CD8+ T cells contribute to survival in patients with COVID-19 and hematologic cancer. Nat. Med. 27, 1280\u20131289 (2021)."},{"key":"274_CR28","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/S0140-6736(21)01462-8","volume":"398","author":"EC Wall","year":"2021","unstructured":"Wall, E. C. et al. AZD1222-induced neutralising antibody activity against SARS-CoV-2 Delta VOC. Lancet 398, 207\u2013209 (2021).","journal-title":"Lancet"},{"key":"274_CR29","doi-asserted-by":"crossref","unstructured":"Wall, E. C. et al. Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination. Lancet 397, 2331\u20132333 (2021).","DOI":"10.1016\/S0140-6736(21)01290-3"},{"key":"274_CR30","doi-asserted-by":"crossref","unstructured":"Carr, E. J. et al. Neutralising antibodies after COVID-19 vaccination in UK haemodialysis patients. Lancet 398, 1038\u20131041 (2021).","DOI":"10.1016\/S0140-6736(21)01854-7"},{"key":"274_CR31","unstructured":"WHO Working Group on the Clinical Characterisation and Management of COVID-19 infection. A minimal common outcome measure set for COVID-19 clinical research. Lancet Infect. Dis. 20, e192\u2013e197 (2020)."},{"key":"274_CR32","doi-asserted-by":"crossref","unstructured":"Thakkar, A. et al. Patterns of seroconversion for SARS-CoV-2 IgG in patients with malignant disease and association with anticancer therapy. Nat. Cancer 2, 392\u2013399 (2021).","DOI":"10.1038\/s43018-021-00191-y"},{"key":"274_CR33","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1016\/j.ccell.2021.07.012","volume":"39","author":"LM Greenberger","year":"2021","unstructured":"Greenberger, L. M. et al. Antibody response to SARS-CoV-2 vaccines in patients with hematologic malignancies. Cancer Cell 39, 1031\u20131033 (2021).","journal-title":"Cancer Cell"},{"key":"274_CR34","doi-asserted-by":"publisher","unstructured":"Shrotri, M. et al. Spike-antibody responses to ChAdOx1 and BNT162b2 vaccines by demographic and clinical factors (Virus Watch study). Preprint at https:\/\/doi.org\/10.1101\/2021.05.12.21257102 (2021).","DOI":"10.1101\/2021.05.12.21257102"},{"key":"274_CR35","doi-asserted-by":"publisher","first-page":"4423","DOI":"10.1016\/j.vaccine.2021.05.063","volume":"39","author":"KA Earle","year":"2021","unstructured":"Earle, K. A. et al. Evidence for antibody as a protective correlate for COVID-19 vaccines. Vaccine 39, 4423\u20134428 (2021).","journal-title":"Vaccine"},{"key":"274_CR36","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1038\/s41586-021-03324-6","volume":"592","author":"Z Wang","year":"2021","unstructured":"Wang, Z. et al. mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. Nature 592, 616\u2013622 (2021).","journal-title":"Nature"},{"key":"274_CR37","doi-asserted-by":"publisher","first-page":"101018","DOI":"10.1016\/j.eclinm.2021.101018","volume":"38","author":"AR Demonbreun","year":"2021","unstructured":"Demonbreun, A. R. et al. Comparison of IgG and neutralizing antibody responses after one or two doses of COVID-19 mRNA vaccine in previously infected and uninfected individuals. EClinicalMedicine 38, 101018 (2021).","journal-title":"EClinicalMedicine"},{"key":"274_CR38","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1038\/s41591-021-01377-8","volume":"27","author":"DS Khoury","year":"2021","unstructured":"Khoury, D. S. et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat. Med. 27, 1205\u20131211 (2021).","journal-title":"Nat. Med."},{"key":"274_CR39","doi-asserted-by":"publisher","unstructured":"Bergwerk, M. et al. COVID-19 breakthrough infections in vaccinated health care workers. N. Engl. J. Med. https:\/\/doi.org\/10.1056\/NEJMoa2109072 (2021).","DOI":"10.1056\/NEJMoa2109072"},{"key":"274_CR40","doi-asserted-by":"crossref","unstructured":"Collier, D. A. et al. Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2. Nature 596, 417\u2013422 (2021).","DOI":"10.1038\/s41586-021-03739-1"},{"key":"274_CR41","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1056\/NEJMoa2108891","volume":"385","author":"J Lopez Bernal","year":"2021","unstructured":"Lopez Bernal, J. et al. Effectiveness of COVID-19 vaccines against the B.1.617.2 (Delta) variant. N. Engl. J. Med. 385, 585\u2013594 (2021).","journal-title":"N. Engl. J. Med."},{"key":"274_CR42","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1016\/S0140-6736(21)00432-3","volume":"397","author":"M Voysey","year":"2021","unstructured":"Voysey, M. et al. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. Lancet 397, 881\u2013891 (2021).","journal-title":"Lancet"},{"key":"274_CR43","doi-asserted-by":"publisher","unstructured":"Parry, H. et al. Extended interval BNT162b2 vaccination enhances peak antibody generation in older people. Preprint at https:\/\/doi.org\/10.1101\/2021.05.15.21257017 (2021).","DOI":"10.1101\/2021.05.15.21257017"},{"key":"274_CR44","doi-asserted-by":"crossref","unstructured":"Kamar, N. et al. Three doses of an mRNA COVID-19 vaccine in solid-organ transplant recipients. N. Engl. J. Med. 385, 661\u2013662 (2021).","DOI":"10.1056\/NEJMc2108861"},{"key":"274_CR45","doi-asserted-by":"crossref","unstructured":"Hall, V. G. et al. Randomized trial of a third dose of mRNA-1273 vaccine in transplant recipients. N. Engl. J. Med. 385, 1244\u20131246 (2021).","DOI":"10.1056\/NEJMc2111462"},{"key":"274_CR46","doi-asserted-by":"crossref","unstructured":"Normark, J. et al. Heterologous ChAdOx1 nCoV-19 and mRNA-1273 vaccination. N. Engl. J. Med. 385, 1049\u20131051 (2021).","DOI":"10.1056\/NEJMc2110716"},{"key":"274_CR47","doi-asserted-by":"crossref","unstructured":"Barros-Martins, J. et al. Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19\/BNT162b2 vaccination. Nat. Med. 27, 1525\u20131529 (2021).","DOI":"10.1038\/s41591-021-01449-9"},{"key":"274_CR48","doi-asserted-by":"crossref","unstructured":"Callaway, E. Mix-and-match COVID vaccines trigger potent immune response. Nature 593, 491 (2021).","DOI":"10.1038\/d41586-021-01359-3"},{"key":"274_CR49","volume":"12","author":"AJ Spencer","year":"2021","unstructured":"Spencer, A. J. et al. Heterologous vaccination regimens with self-amplifying RNA and adenoviral COVID vaccines induce robust immune responses in mice. Nat. Commun. 12, 2893 (2021).","journal-title":"Nat. Commun."},{"key":"274_CR50","doi-asserted-by":"crossref","unstructured":"Hill, J. A., Ujjani, C. S., Greninger, A. L., Shadman, M. & Gopal, A. K. Immunogenicity of a heterologous COVID-19 vaccine after failed vaccination in a lymphoma patient. Cancer Cell 39, 1037\u20131038 (2021).","DOI":"10.1016\/j.ccell.2021.06.015"},{"key":"274_CR51","doi-asserted-by":"publisher","first-page":"100355","DOI":"10.1016\/j.xcrm.2021.100355","volume":"2","author":"A Tarke","year":"2021","unstructured":"Tarke, A. et al. Impact of SARS-CoV-2 variants on the total CD4+ and CD8+ T cell reactivity in infected or vaccinated individuals. Cell Rep. Med. 2, 100355 (2021).","journal-title":"Cell Rep. Med."},{"key":"274_CR52","doi-asserted-by":"publisher","first-page":"eabl4509","DOI":"10.1126\/sciimmunol.abl4509","volume":"6","author":"B Israelow","year":"2021","unstructured":"Israelow, B. et al. Adaptive immune determinants of viral clearance and protection in mouse models of SARS-CoV-2. Sci. Immunol. 6, eabl4509 (2021).","journal-title":"Sci. Immunol."},{"key":"274_CR53","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1038\/s41586-020-03041-6","volume":"590","author":"K McMahan","year":"2021","unstructured":"McMahan, K. et al. Correlates of protection against SARS-CoV-2 in rhesus macaques. Nature 590, 630\u2013634 (2021).","journal-title":"Nature"},{"key":"274_CR54","doi-asserted-by":"publisher","unstructured":"Apostolidis, S. A. et al. Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy. Nat. Med. https:\/\/doi.org\/10.1038\/s41591-021-01507-2 (2021).","DOI":"10.1038\/s41591-021-01507-2"},{"key":"274_CR55","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-002266","volume":"9","author":"A Passaro","year":"2021","unstructured":"Passaro, A. et al. Severity of COVID-19 in patients with lung cancer: evidence and challenges. J. Immunother. Cancer 9, e002266 (2021).","journal-title":"J. Immunother. Cancer"},{"key":"274_CR56","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.ejca.2020.09.027","volume":"141","author":"K de Joode","year":"2020","unstructured":"de Joode, K. et al. Dutch Oncology COVID-19 Consortium: outcome of COVID-19 in patients with cancer in a nationwide cohort study. Eur. J. Cancer 141, 171\u2013184 (2020).","journal-title":"Eur. J. Cancer"},{"key":"274_CR57","doi-asserted-by":"crossref","unstructured":"Pritchard, E. et al. Impact of vaccination on new SARS-CoV-2 infections in the United Kingdom. Nat. Med. 27, 1370\u20131378 (2021).","DOI":"10.1038\/s41591-021-01410-w"},{"key":"274_CR58","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1053\/j.seminoncol.2017.06.002","volume":"44","author":"P Fessas","year":"2017","unstructured":"Fessas, P., Lee, H., Ikemizu, S. & Janowitz, T. A molecular and preclinical comparison of the PD-1-targeted T-cell checkpoint inhibitors nivolumab and pembrolizumab. Semin. Oncol. 44, 136\u2013140 (2017).","journal-title":"Semin. Oncol."},{"key":"274_CR59","doi-asserted-by":"publisher","first-page":"e69317","DOI":"10.7554\/eLife.69317","volume":"10","author":"N Faulkner","year":"2021","unstructured":"Faulkner, N. et al. Reduced antibody cross-reactivity following infection with B.1.1.7 than with parental SARS-CoV-2 strains. eLife 10, e69317 (2021).","journal-title":"eLife"},{"key":"274_CR60","doi-asserted-by":"publisher","first-page":"e3001091","DOI":"10.1371\/journal.pbio.3001091","volume":"19","author":"SJ Rihn","year":"2021","unstructured":"Rihn, S. J. et al. A plasmid DNA-launched SARS-CoV-2 reverse genetics system and coronavirus toolkit for COVID-19 research. PLoS Biol. 19, e3001091 (2021).","journal-title":"PLoS Biol."},{"key":"274_CR61","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1128\/JVI.79.3.1635-1644.2005","volume":"79","author":"EN van den Brink","year":"2005","unstructured":"van den Brink, E. N. et al. Molecular and biological characterization of human monoclonal antibodies binding to the spike and nucleocapsid proteins of severe acute respiratory syndrome coronavirus. J. Virol. 79, 1635\u20131644 (2005).","journal-title":"J. Virol."},{"key":"274_CR62","doi-asserted-by":"publisher","unstructured":"Adriana, T. et al. Divergent trajectories of antiviral memory after SARS-CoV-2 infection. Preprint at https:\/\/doi.org\/10.21203\/rs.3.rs-612205\/v1 (2021).","DOI":"10.21203\/rs.3.rs-612205\/v1"}],"container-title":["Nature Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s43018-021-00274-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43018-021-00274-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43018-021-00274-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T15:53:08Z","timestamp":1670082788000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s43018-021-00274-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,27]]},"references-count":62,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["274"],"URL":"https:\/\/doi.org\/10.1038\/s43018-021-00274-w","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-916303\/v1","asserted-by":"object"}]},"ISSN":["2662-1347"],"issn-type":[{"value":"2662-1347","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,27]]},"assertion":[{"value":"18 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.T. has received speaking fees from Roche, AstraZeneca, Novartis and Ipsen. S.T. has filed the following patents: \u2018Indel mutations as a therapeutic target and predictive biomarker\u2019 (PCTGB2018\/051892 and PCTGB2018\/051893) and \u2018Clear Cell Renal Cell Carcinoma Biomarkers\u2019 (P113326GB). N.Y. has received conference support from Celgene. A. Rogiers received a speaker fee from Merck Sharp & Dohme. J.L. received research funding from Bristol Myers Squibb, Merck, Novartis, Pfizer, Achilles Therapeutics, Roche, Nektar Therapeutics, Covance, Immunocore, Pharmacyclics and Aveo and served as a consultant to Achilles, AstraZeneca, Boston Biomedical, Bristol Myers Squibb, Eisai, EUSA Pharma, GlaxoSmithKline, Ipsen, Imugene, Incyte, iOnctura, Kymab, Merck Serono, Nektar, Novartis, Pierre Fabre, Pfizer, Roche Genentech, Secarna and Vitaccess. I.C. has served as a consultant to Eli Lilly, Bristol Meyers Squibb, MSD, Bayer, Roche, Merck Serono, Five Prime Therapeutics, AstraZeneca, OncXerna, Pierre Fabre, Boehringer Ingelheim, Incyte, Astellas, GSK, Sotio and Eisai and has received research funding from Eli Lilly and Janssen-Cilag. He has received honoraria from Eli Lilly, Eisai and Servier. A.O. acknowledges receipt of research funding from Pfizer and Roche; speaker fees from Pfizer, Seagen, Lilly and AstraZeneca; is an advisory board member of Roche, Seagen and AstraZeneca; has received conference support from Leo Pharmaceuticals, AstraZeneca\u2013Daiichi Sankyo and Lilly. C. Swanton acknowledges grant support from Pfizer, AstraZeneca, Bristol Myers Squibb, Roche\u2013Ventana, Boehringer Ingelheim, ArcherDx (collaboration in minimal residual disease sequencing technologies) and Ono Pharmaceutical; is an AstraZeneca advisory board member and the chief investigator for the MeRmaiD1 clinical trial; has consulted for Amgen, Pfizer, Novartis, GlaxoSmithKline, MSD, Bristol Myers Squibb, Celgene, AstraZeneca, Illumina, Genentech, Roche\u2013Ventana, GRAIL, Medicxi, Metabomed, Bicycle Therapeutics and the Sarah Cannon Research Institute; has stock options in ApoGen Biotechnologies, Epic Bioscience and GRAIL; and has stock options in and is a cofounder of Achilles Therapeutics. C. Swanton holds European patents relating to assay technology to detect tumor recurrence (PCT\/GB2017\/053289), target neoantigens (PCT\/EP2016\/059401), identify patient response to immune-checkpoint blockade (PCT\/EP2016\/071471), determine HLA LOH (PCT\/GB2018\/052004), predict survival rates of patients with cancer (PCT\/GB2020\/050221) and identify patients who respond to cancer treatment (PCT\/GB2018\/051912); a US patent related to detecting tumor mutations (PCT\/US2017\/28013); and both a European and US patent related to identifying insertion and deletion mutation targets (PCT\/GB2018\/051892). L.P. has received research funding from Pierre Fabre and honoraria from Pfizer, Ipsen, Bristol Myers Squibb and EUSA Pharma. S. Banerjee has received institutional research funding from AstraZeneca, Tesaro and GSK; speaker fees from Amgen, Pfizer, AstraZeneca, Tesaro, GSK, Clovis, Takeda, ImmunoGen and Mersana; and has an advisor role for Amgen, AstraZeneca, Epsilogen, Genmab, ImmunoGen, Mersana, MSD, Merck Serono, OncXerna, Pfizer and Roche. W.C. has received honoraria from Janssen and AstraZeneca. A.F., S.T.C.S., L.A., K.A.W., M.W., F.B., M.C., A.M.S., N.J.-H., B.S., Z.T., K.R., L.A.B., R.H., E.C., K.E., L.D.R., S.S., K.L., M.M., L.H., H.A., J.K., T.F., J.B., W.G., T.B., A.E.-H., W.X., C.L.G., D.D., E.C.W., A.A.-D., S.N., S.C., M.G., J.I.M., G. Kelly, K.P., D.K., A.M., K.K., M.O\u2019F., L.D., N.A., F.G., R.L.S., G.G., D.M., F.K., W.C., J.P., S.R., J.M., O.C., C. Stephenson, B.O., S.F., I.L., A. Reid, S.I., M.E., C.M., D.C., N.S., N.T., L.W., N.v.A., R.L.J., J.D., K.C.T., M.O\u2019B., K.H., S. Bhide, K.Y., A.J.S.F., S. Gamblin, D.L.V.B., G. Kassiotis, S.K., N.Y., S.J., E.N., M.H., S.W. and R.J.W. have no conflicts of interest to declare.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}